New Stock News | Libang Pharmaceutical is making a breakthrough in the Hong Kong stock market: Meixinluo supports the commercialization foundation, and AP306 is going global beyond imagination.

On May 4th, LaiBang Medicine submitted its prospectus to the Hong Kong Stock Exchange, planning to debut on the Hong Kong stock market. As an innovative pharmaceutical company focusing on kidney diseases and related complications, the highlight of LaiBang Medicine's prospectus submission this time is not only about building a multi-level pipeline around chronic kidney disease, but also about the company transitioning from early-stage "research and development-driven" to "research and development + commercialization" dual-driven approach. On one hand, the commercialized product Mircera has seen rapid growth in the Chinese market, driving the company's revenue and gross profit margin to increase simultaneously. On the other hand, the core candidate product AP306, through overseas collaboration with R1 Therapeutics, has explored an international path that balances risk-sharing and long-term profit sharing. The prospectus shows that LaiBang Medicine's current pipeline covers areas such as hyperphosphatemia, anemia related to chronic kidney disease, autosomal dominant polycystic kidney disease, IgA nephropathy, etc., and has formed a line-up consisting of commercialized products, late-stage clinical assets, and early-stage projects. Commercialization validation: Mircera volume drives 370% revenue growth For an innovative pharmaceutical company, research and development capabilities determine long-term potential, while commercialization capabilities determine the speed of value realization. A major highlight of LaiBang Medicine's prospectus this time is its establishment of a commercial revenue base through Mircera. The prospectus shows that from 2024 to 2025, the company's operating income increased significantly from 6.525 million yuan to 30.556 million yuan, a year-on-year growth rate of 368.3%, with the nearly 370% high-speed growth driven entirely by the rapid volume growth of the core commercialized product Mircera. Mircera is the world's only approved once-monthly long-acting erythropoiesis-stimulating agent (ESA) for the treatment of CKD-related anemia, and LaiBang Medicine has its exclusive commercialization rights in China. The product was officially launched in China in 2024 and has significantly improved patient compliance due to its once-monthly dosing advantage. It is now included in the 2023 National Medical Insurance Catalog, covering over 300 hospitals nationwide, with the clinical prescription habits continuing to penetrate. The prospectus discloses that in 2025, the company's commercialization investment in Mircera reached 9.583 million yuan, an increase of 109.6% compared to 2024, with the expansion of the sales team and deepening of academic promotion laying a solid foundation for the product's continued growth. While revenue is growing, the company's profit quality has also significantly improved. In 2025, the company's comprehensive gross profit margin reached 44.0%, a 7.4 percentage point increase from 2024's 36.6%, mainly benefiting from the expansion of Mircera sales which optimized the cost structure - the proportion of product purchase costs increased, while the proportion of fixed amortization costs decreased, showing initial scale effects. AP306 going global: Binding long-term value with "licensing + equity" If Mircera validates LaiBang Medicine's commercial execution in the Chinese market, then AP306 is the core asset of the company's global narrative. Hyperphosphatemia is a common complication of chronic kidney disease, especially in dialysis patients. In 2024, the global market size of hyperphosphatemia drugs reached $1.5 billion, expected to increase to $6 billion by 2035. The Chinese hyperphosphatemia drug market reached 2.4 billion yuan in 2024 and is expected to grow to 12.5 billion yuan by 2035. The prospectus shows that AP306 is an oral phosphate transporter inhibitor targeting three key phosphate transporters in the intestines, NaPi-IIb, PiT-1, and PiT-2, used to treat hyperphosphatemia. The company claims that AP306 is the world's first and as of the last feasible date clinically developed phosphate transporter inhibitor for the treatment of hyperphosphatemia. Traditional treatments for hyperphosphatemia often rely on phosphate binders, but there have been long-standing challenges with medication burden and compliance. The differentiation of AP306 lies in its mechanism of action, as it does not physically bind phosphate in the gastrointestinal tract but inhibits active transport to reduce phosphate absorption, possessing innovative mechanism properties. In terms of clinical data, the prospectus reveals that in completed phase II clinical trials in China, the average reduction in blood phosphorus levels for the AP306 group was 2.51 mg/dL; by the 7th or 8th week, nearly 95% of patients had controlled blood phosphorus levels. In terms of safety, the most common adverse events were gastrointestinal reactions, mostly mild to moderate diarrhea, with a discontinuation rate due to adverse events of less than 5%. Additionally, the average daily dose of AP306 was 288 82 mg, significantly lower than the active control sevelamer's 4651 1899 mg. In December 2025, LaiBang Medicine entered into a collaboration and licensing agreement with R1 Therapeutics for AP306. According to the prospectus, the company granted R1 the exclusive license to develop, manufacture, and commercialize AP306 in regions outside mainland China, Hong Kong, Macau, and Taiwan, while retaining full rights in the Greater China region. R1 will bear the primary financial responsibility for global clinical development of AP306 in the licensed area; both parties will conduct phase IIb and subsequent phase III clinical trials in their respective regions and share the data required for regulatory approval. The structure of this transaction is quite interesting. LaiBang Medicine not only has the right to receive up to several hundred million US dollars in regulatory and commercial milestone payments, but will also hold a significant minority stake in R1 and set up an anti-dilution protection mechanism; after the expected listing of AP306, when net sales exceed $1 billion in that year, the company may be entitled to receive a tiered franchise fee of 1% to 4% based on annual net sales. This means that LaiBang Medicine's global expansion of AP306 is not simply a one-time sale, but through licensing, milestones, franchise fees, and equity binding, it retains the space to share long-term value brought by future global commercial success. Industrial capital participation: Accelerating global development of AP306 R1's own industry resources have also enhanced the certainty of AP306's overseas development. In March 2026, R1 announced the completion of an oversubscribed $75 million Series A financing round led by Abingworth, DaVita Venture Group, and F-Prime Capital, with participation from Curie.Bio, SymBiosis, and U.S. Renal Care; R1 also announced that it had obtained the global exclusive rights to develop and commercialize AP306 outside the Greater China region. DaVita is a U.S. publicly traded company and a major global provider of kidney disease and dialysis services; U.S. Renal Care is a large private dialysis service provider in the United States. Together, they have a combined market share of over 50% in the U.S. dialysis market. For AP306 targeting high phosphorus levels in dialysis patients, the participation of such industry players not only signifies capital support but also brings clinical insights, patient management experience, and market access resources. According to the prospectus, the company and R1 are expected to initiate a multi-center phase IIb clinical trial of AP306 in the second quarter of 2026 and complete the trial in the second quarter of 2027. If successful, AP306 is expected to become an important asset for LaiBang Medicine connecting Chinese innovation research and the global kidney disease market. AP301 nearing declaration, pipeline entering monetization window While advancing the internationalization of AP306, another core product of LaiBang Medicine, AP301, is also approaching a commercialization milestone. The prospectus shows that AP301 is a phosphate binder used to treat hyperphosphatemia in chronic kidney disease patients on maintenance dialysis. Currently, the phase III clinical trial of AP301 in China has been completed, and the company is expected to submit a new drug listing application to the China National Medical Products Administration in the second quarter of 2026; a global multi-center phase III clinical trial in the U.S. region is ongoing, with completion expected in the second quarter of 2027, and submission of a New Drug Application (NDA) to the FDA in the third quarter of 2027. Additionally, the company also plans to initiate a clinical trial for non-dialysis chronic kidney disease patients with hyperphosphatemia using AP301 in 2028 to further expand its potential patient population. In addition to AP301 and AP306, the company's pipeline is also advancing. AP303 is a novel disease-modifying product for the progression of chronic kidney disease, intended for diseases such as diabetic kidney disease and IgA nephropathy; AP308 is a novel IgA protease aimed at treating IgA nephropathy. According to the prospectus, the company plans to start a phase II basket trial of AP303 in China and Australia in the third quarter of 2026 and expects to submit an IND application for AP308 to the China National Medical Products Administration and the FDA in the third quarter of 2026. To support pipeline progress, the company continues to increase research and development investment. In 2025, LaiBang Medicine's research and development spending reached 373 million yuan, a 58.3% increase from 235 million yuan in 2024. Among these, a significant portion of research and development investment is allocated to the core product AP301, primarily for global multi-center phase III clinical trials and registration applications. Cash reserves of 530 million yuan, IPO supporting accelerated research and commercialization Sufficient funding reserves are essential for LaiBang Medicine to continue pushing forward with research and commercialization. As of December 31, 2025, the company's cash and cash equivalents balance was 358.3 million yuan, supplemented by time deposits of 27.375 million yuan and financial assets recorded at fair value of 145.5 million yuan, with a total cash reserve of approximately 531 million yuan. The prospectus reveals that the IPO proceeds will mainly be used for clinical development and regulatory affairs of core products AP301 and other candidate drugs, establishment of commercialization capabilities and market promotion for AP301, Mircera, and other products, upgrading of the Yangzhou production base, as well as to supplement working capital and for general corporate purposes. The company also plans to establish a professional sales team of 150 to 200 people within the first three years after AP301's listing in preparation for the commercialization ramp-up of future products. From commercialization landing to global equity sharing From the commercialization growth of Mircera to the international licensing of AP306 and the nearing launch application of AP301, LaiBang Medicine is forming a development loop of "commercial revenue - clinical advancement - global collaboration." Amidst the financing, research and development investment, and commercialization pressure faced by many Hong Kong 18A companies, the differentiation of LaiBang Medicine lies in: having already established an income and gross profit base through Mircera, and building an overseas value-sharing mechanism early through AP306 collaboration. In the short term, key indicators to observe the company's commercialization capability will include the number of hospitals covered by Mircera, sales volume, and gross profit margin improvement; in the medium to long term, this entry into the Hong Kong capital market will provide the company with more substantial financial support and a broader development platform, accelerating pipeline progress and global deployment, steadily moving towards becoming a leading global kidney disease innovation platform.